Codex Dna Releases Full-Length Synthetic Genome for Highly Infectious Sars-Cov-2 Delta Variant
September 01, 2021 at 04:15 pm EDT
Share
Codex DNA, Inc. announced the release of its first full-length synthetic genome for the highly infectious Delta variant of the SARS-CoV-2 virus (B.1.617 lineage). The genome was synthesized and constructed using Codex DNA’s BioXp™ 3250 system, its fully automated synthetic biology benchtop workstation for rapid, accurate, and reproducible writing of DNA and mRNA. The Codex DNA synthetic SARS-CoV-2 genomes can be used by researchers to generate breakthrough therapies and vaccines and to develop new diagnostics to help detect, contain, and slow the spread of highly transmissible variants. Synthetic genomes allow scientists to work safely with the replicated virus without the additional security measures required when working with the actual pathogen and therefore have allowed more laboratories to engage in the battle against the pandemic than would otherwise have been possible.Codex DNA provides fully automated, benchtop synthetic biology solutions for accelerating timelines for vaccine development and biologics drug discovery. The company currently offers a catalogue of 13 SARS-CoV-2 synthetic genomes as well as custom-made SARS-CoV-2 genomes that are used for developing or testing monoclonal antibody treatments, small-molecule therapies, or new vaccines against specific variants. These genomes may also serve as diagnostic controls. In addition, Codex DNA offers a suite of RNA controls and custom DNA synthesis services to address SARS-CoV-2. For customers interested in alternative variants to SARS-CoV-2, Codex DNA provides a wide range of synthetic controls that enable scientists to confidently verify and validate assays without the need for clinical virus samples.
Telesis Bio Inc. is a provider of ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) solutions. The Company provides automated multi-omic and synthetic biology solutions focused on providing applications to enable researchers to rapidly and reproducibly build or write high-quality synthetic DNA and messenger Ribonucleic Acid (mRNA) and short oligonucleotides that are ready to use in many downstream synthetic biology enabled markets. Its BioXp system consolidates, automates, and optimizes the entire synthesis, cloning and amplification workflow. Its on-market and its planned solutions include BioXp 3250 system, BioXp 9600 system, BioXp portal, BioXp De Novo kits, BioXp Select kits, BioXp Next Generation Sequencing kits, Benchtop reagents and Custom Gibson Short Oligo Ligation Assembly (SOLA) enzymatic DNA synthesis (EDS) solutions. BioXp Select kits offer customers the ability to use non-Telesis Bio DNA while using the BioXp system to perform synthetic biology workflow applications.